

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016

Email: shreeganeshbiotechindia1td@gmail.com Website: www.shreeganeshbiotech.club

Date: 14.02.2023

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock Exchange
Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of India
Limited
Vibgyor Towers, 4th floor, Plot No C 62,
Opp. Trident Hotel Bandra Kurla Complex,
Bandra (E),
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir / Madam,

Sub: Outcome of the Board Meeting of the board held on 14.02.2023

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith unaudited financial result for quarter ended 31st December 2022 and board meeting concluded on 13.15 P.M.

Kindly take the same on your record and oblige.

Thanking You.

Yours faithfully,
For, SHREE GANESH BIO-TECH (INDIA) LIMITED

Director/Authorised Signatory



Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindia@gmail.com

Statement of Standalone Financial Results for the quarter ended on December 31, 2022

Particulars		Quarter Ended			Nine Months Ended		Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
A	Date of start of reporting period	01-10-2022	01-07-2022	01-10-2021	01-04-2022	01-04-2021	01-04-2021
B	Date of end of reporting period	31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
I	Revenue From Operations						
	Net sales or Revenue from Operations	1,207.30	2,175.63	1,902.90	5,447.70	5,250.50	7,264.42
II	Other Income	0.10	1.41	0.23	(1.94)	5.06	5.06
III	Total Income (I+II)	1,207.40	2,177.04	1,903.13	5,445.76	5,255.56	7,269.48
IV	Expenses						
(a)	Cost of materials consumed	1,174.60	2,041.95	1,801.14	5,153.04	4,983.49	6,883.64
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	3.83	5.56	6.29	15.68	18.25	24.54
(e)	Finance Costs	-	-	-	-	-	0.01
(f)	Depreciation and amortisation expense	-	-	-	-	-	0.06
(g)	Other Expenses	2.04	9.52	0.69	15.26	8.18	11.28
	Total expenses (IV)	1,180.47	2,057.03	1,808.12	5,183.98	5,009.92	6,919.53
V	Profit/(loss) before exceptional items and tax (III-IV)	26.93	120.01	95.01	261.78	245.64	349.95
VI	Exceptional items	-	-	-	-	-	-
VII	Profit (loss) after exceptional items and before Tax (V-VI)	26.93	120.01	95.01	261.78	245.64	349.95
VIII	Tax Expense						
(a)	Current Tax	-	-	-	-	-	97.36
(b)	(Less):- MAT Credit	-	-	-	-	-	-
(c)	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(d)	Deferred Tax (Asset)/Liabilities	-	-	-	-	-	-
IX	Profit (Loss) after Tax for the period (VII-VIII)	26.93	120.01	95.01	261.78	245.64	252.59
X	Other Comprehensive Income						
	a. i). Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b. i). Item that will be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive income	-	-	-	-	-	-
XI	Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	26.93	120.01	95.01	261.78	245.64	252.59
XII	Details of equity share capital						
	Paid-up equity share capital	3,986.24	3,986.24	1,993.12	3,986.24	1,993.12	1,993.12
	Face value of equity share capital (Per Share)	1.00	1.00	1.00	1.00	1.00	1.00
XIII	Other Equity	-	-	-	-	-	4,038.68
XIV	Earnings per share						
(a)	Earnings per share (not annualised for quarter ended)						
	Basic earnings (loss) per share from continuing operation	0.01	0.03	0.05	0.07	0.12	0.13
	Diluted earnings (loss) per share from continuing operation	0.01	0.03	0.05	0.07	0.12	0.13



Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126,3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindia@gmail.com


Notes on Financial Results:-

1	The above unaudited standalone financial results for the quarter ended December 31, 2022 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on February 14, 2023. The statutory auditors have carried out limited review of above result.
2	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
3	As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment.
4	The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
5	Earning Per Share (EPS) for current and previous periods are recalculated, as per the new Face Value of Rs. 1/- per share, consequent to the sub-division of Equity Shares.
6	Provision for Taxation if any will be made at year end.

For, Shree Ganesh Biotech (India) Limited

Date :- 14th February, 2023

Place:- Kolkata





Limited Review Report

To

The Board of Directors of
SHREE GANESH BIOTECH (INDIA) LIMITED
Kolkata


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SHREE GANESH BIOTECH (INDIA) LIMITED** ("the Company"), for the Quarter ended on December 31, 2022 and year to date result for the period from 01 April, 2022 to 31 December, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah
Partner
M. No.: 126337
UDIN: 23126337BGSPFT7346
Place: Vadodara
Date: 14.02.2023

